A neuromuscular drug candidate acquired through Novartis’s (NVS) $12 billion Avidity Biosciences deal missed its late-stage primary endpoint, compounding a difficult stretch for the Swiss drugmaker’s pipeline.
The setback raises fresh questions about the return on Novartis’s largest recent acquisition and narrows the near-term earnings contribution expected from the Avidity asset tranche – a concern for investors tracking the company’s post-deal pipeline conversion rate.
Key Takeaways
- Avidity-derived neuromuscular candidate fails late-stage primary endpoint.
- Asset was one of three therapies in the $12 billion Avidity deal.
- Novartis also reported a Phase 3 cardiovascular failure days earlier.
Pipeline Pressure Builds After Back-to-Back Trial Failures
The neuromuscular miss arrives less than a week after Novartis said its cardiovascular drug pelacarsen failed the Phase 3 HORIZON trial, unable to reduce the risk of cardiovascular death, heart attacks, or stroke compared with placebo 1. Two high-profile Phase 3 failures within a single week place Novartis in a difficult position relative to large-cap pharma peers that have recently logged late-stage wins in adjacent therapeutic categories.
Pelacarsen had generated significant investor interest as a potential blockbuster targeting elevated lipoprotein(a), or Lp(a) – a lipid marker linked to increased cardiovascular risk. Rivals including Amgen and Eli Lilly are still advancing their own Lp(a)-lowering programs, meaning Novartis has effectively ceded early-mover advantage in that space 2.
The Avidity Acquisition Under the Microscope
Novartis closed its acquisition of Avidity Biosciences for approximately $12 billion, adding three pipeline therapies in one transaction – a scale of M&A that drew attention across the biotech consolidation landscape 1. The neuromuscular candidate that failed was among that trio, meaning the deal’s remaining value now rests on just two surviving assets.
For macro and sector investors tracking M&A velocity in biotech, the outcome illustrates the binary risk embedded in large single-bolt-on deals when the underlying pipeline is still in late-stage development. This dynamic mirrors patterns seen elsewhere in recent biotech consolidation, including gene-therapy programs halted mid-trial after acquisition, where acquirer balance sheets absorbed clinical risk without the commercial upside.
Neuromuscular Landscape and Competitive Context
The neuromuscular disease space has attracted substantial capital given the relative scarcity of approved therapies and the high unmet need in conditions such as myotonic dystrophy and Duchenne muscular dystrophy. A Phase 3 failure in this area typically resets the clinical timeline by several years, removing a near-term revenue catalyst that analysts may have partially priced into valuation models.
Novartis has faced pipeline headwinds in other advanced therapeutic modalities as well; the company’s CAR-T and autoimmune programs have also encountered development friction, as outlined in earlier reporting on its autoimmune trial challenges. Taken together, the setbacks suggest that execution across the company’s expanded pipeline warrants close scrutiny from shareholders.
Management Position and Investor Implications
Novartis had not issued a detailed public statement beyond confirming the trial miss at the time of this report; the company is expected to address next steps for the program – including whether any subgroup analyses or alternative indications could support continued development – at its next scheduled investor update.
“Other pharmaceutical companies, including Amgen and Eli Lilly, are also developing therapies to lower levels of Lp(a),” STAT News noted in its coverage of the pelacarsen failure, underscoring the competitive stakes Novartis faces across multiple fronts 2.
For retail investors, the immediate calculus centres on how much of the Avidity deal’s value has now been impaired and whether management will pursue a write-down, a revised commercial outlook, or a reallocation of capital toward the two remaining Avidity assets. The stock’s reaction to the cumulative news flow will be a key signal of market confidence in Novartis’s pipeline execution going forward.
Conclusion
Two Phase 3 failures in rapid succession – one in cardiovascular disease, one in neuromuscular medicine – represent a material setback for Novartis’s near-term pipeline story and call into question the risk-adjusted value of its $12 billion Avidity bet. With competitors advancing in both therapeutic areas, the pressure on management to demonstrate returns from remaining pipeline assets is intensifying.
Not investment advice. For informational purposes only.
References
1(2026-09-08). “Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial”. The Wall Street Journal. Retrieved 2026-09-08.
2Andrew Joseph (2026-09-04). “Novartis’ experimental cardiovascular drug fails a pivotal study”. STAT News. Retrieved 2026-09-08.